| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
|
Coleman, Robert
|
|
|
21 |
1 |
p. 60-72
|
artikel
|
| 2 |
Androgen deprivation therapy plus salvage radiotherapy after prostatectomy
|
Ghadjar, Pirus
|
|
|
21 |
1 |
p. e11
|
artikel
|
| 3 |
Androgen deprivation therapy plus salvage radiotherapy after prostatectomy
|
Birer, Samuel
|
|
|
21 |
1 |
p. e12
|
artikel
|
| 4 |
Androgen deprivation therapy plus salvage radiotherapy after prostatectomy – Authors' reply
|
Carrie, Christian
|
|
|
21 |
1 |
p. e13
|
artikel
|
| 5 |
A new standard of care for patients with high-risk rhabdomyosarcoma?
|
Italiano, Antoine
|
|
|
21 |
1 |
p. e2
|
artikel
|
| 6 |
A new standard of care for patients with high-risk rhabdomyosarcoma?
|
Koscielniak, Ewa
|
|
|
21 |
1 |
p. e1
|
artikel
|
| 7 |
A new standard of care for patients with high-risk rhabdomyosarcoma? – Authors' reply
|
Bisogno, Gianni
|
|
|
21 |
1 |
p. e3
|
artikel
|
| 8 |
A promising start for checkpoint inhibitors in childhood malignancies
|
Tawbi, Hussein
|
|
|
21 |
1 |
p. 13-14
|
artikel
|
| 9 |
Are ethics always humane?
|
Malik, Deepika
|
|
|
21 |
1 |
p. 31-32
|
artikel
|
| 10 |
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study
|
Spunt, Sheri L
|
|
|
21 |
1 |
p. 145-161
|
artikel
|
| 11 |
Artificial intelligence applications in upper gastrointestinal cancers
|
Li, Jialin
|
|
|
21 |
1 |
p. e4
|
artikel
|
| 12 |
Artificial intelligence applications in upper gastrointestinal cancers – Authors' reply
|
Luo, Huiyan
|
|
|
21 |
1 |
p. e5
|
artikel
|
| 13 |
2019 ASH Annual Meeting
|
Yaqub, Farhat
|
|
|
21 |
1 |
p. 27
|
artikel
|
| 14 |
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study
|
Geoerger, Birgit
|
|
|
21 |
1 |
p. 134-144
|
artikel
|
| 15 |
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
|
Schmid, Peter
|
|
|
21 |
1 |
p. 44-59
|
artikel
|
| 16 |
Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
|
Nuzzolese, Imperia
|
|
|
21 |
1 |
p. 21-24
|
artikel
|
| 17 |
Building momentum for subsets of patients with advanced triple-negative breast cancer
|
Woodward, Wendy A
|
|
|
21 |
1 |
p. 3-5
|
artikel
|
| 18 |
Cancer and five chemicals: why we still don't know whether there is a risk to humans
|
McConway, Kevin
|
|
|
21 |
1 |
p. 20-21
|
artikel
|
| 19 |
Carcinogenicity of some industrial chemical intermediates and solvents
|
|
|
|
21 |
1 |
p. 25-26
|
artikel
|
| 20 |
Cardiac metastasis from non-visceral sarcoma
|
Wang, Wei-Jun
|
|
|
21 |
1 |
p. e66
|
artikel
|
| 21 |
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|
Guckenberger, Matthias
|
|
|
21 |
1 |
p. e18-e28
|
artikel
|
| 22 |
Correction to Lancet Oncol 2019; 20: 1432–43
|
|
|
|
21 |
1 |
p. e14
|
artikel
|
| 23 |
Critical treatment choices for patients with platinum-refractory urothelial carcinoma
|
Lotan, Yair
|
|
|
21 |
1 |
p. 11-13
|
artikel
|
| 24 |
Denosumab in early breast cancer: negative data and a call to action
|
Perrone, Francesco
|
|
|
21 |
1 |
p. 5-6
|
artikel
|
| 25 |
Earlier diagnosis: the importance of cancer symptoms
|
Whitaker, Katriina
|
|
|
21 |
1 |
p. 6-8
|
artikel
|
| 26 |
Hong Kong: long civil unrest with long-term consequences
|
The Lancet Oncology,
|
|
|
21 |
1 |
p. 1
|
artikel
|
| 27 |
How public health services pay for radiotherapy in Europe: an ESTRO–HERO analysis of reimbursement
|
Lievens, Yolande
|
|
|
21 |
1 |
p. e42-e54
|
artikel
|
| 28 |
Immune checkpoint inhibitors and tuberculosis: an old disease in a new context
|
Langan, Ewan A
|
|
|
21 |
1 |
p. e55-e65
|
artikel
|
| 29 |
Immune checkpoint inhibitors for refractory childhood cancers
|
Widemann, Brigitte C
|
|
|
21 |
1 |
p. 14-15
|
artikel
|
| 30 |
Immunoglobulin replacement and quality of life after CAR T-cell therapy
|
Misbah, Siraj A
|
|
|
21 |
1 |
p. e6
|
artikel
|
| 31 |
Immunoglobulin replacement and quality of life after CAR T-cell therapy – Authors' reply
|
Laetsch, Theodore W
|
|
|
21 |
1 |
p. e7
|
artikel
|
| 32 |
Intelligence outcomes after proton versus photon therapy
|
Das, Manjulika
|
|
|
21 |
1 |
p. e16
|
artikel
|
| 33 |
Is thermal ablation a new standard for cervical pre-cancer treatment in low-income and middle-income countries?
|
Petignat, Patrick
|
|
|
21 |
1 |
p. 19-20
|
artikel
|
| 34 |
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|
Mateo, Joaquin
|
|
|
21 |
1 |
p. 162-174
|
artikel
|
| 35 |
Osimertinib for leptomeningeal metastases in NSCLC
|
Gourd, Elizabeth
|
|
|
21 |
1 |
p. e17
|
artikel
|
| 36 |
Overall survival with osimertinib in untreated NSCLC
|
Gourd, Elizabeth
|
|
|
21 |
1 |
p. e15
|
artikel
|
| 37 |
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|
Geoerger, Birgit
|
|
|
21 |
1 |
p. 121-133
|
artikel
|
| 38 |
Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study
|
Koo, Minjoung Monica
|
|
|
21 |
1 |
p. 73-79
|
artikel
|
| 39 |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
|
Petrylak, Daniel P
|
|
|
21 |
1 |
p. 105-120
|
artikel
|
| 40 |
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
|
Prat, Aleix
|
|
|
21 |
1 |
p. 33-43
|
artikel
|
| 41 |
Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children
|
Martin-Broto, Javier
|
|
|
21 |
1 |
p. 16-17
|
artikel
|
| 42 |
Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial
|
van der Hout, Anja
|
|
|
21 |
1 |
p. 80-94
|
artikel
|
| 43 |
San Antonio Breast Cancer Symposium 2019
|
Gourd, Katherine
|
|
|
21 |
1 |
p. 28
|
artikel
|
| 44 |
Second-line therapies in advanced biliary tract cancers
|
Tella, Sri Harsha
|
|
|
21 |
1 |
p. e29-e41
|
artikel
|
| 45 |
Sequencing therapy for advanced renal cancer
|
Bex, Axel
|
|
|
21 |
1 |
p. 9-11
|
artikel
|
| 46 |
Technology is the future, but who are we leaving behind?
|
Nicklin, Emma
|
|
|
21 |
1 |
p. 29
|
artikel
|
| 47 |
The Following Scan Will Last Five Minutes
|
Swain, Kelley
|
|
|
21 |
1 |
p. 30-31
|
artikel
|
| 48 |
Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial
|
Pinder, Leeya F
|
|
|
21 |
1 |
p. 175-184
|
artikel
|
| 49 |
The role of self-management in cancer survivorship care
|
Girgis, Afaf
|
|
|
21 |
1 |
p. 8-9
|
artikel
|
| 50 |
The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer
|
Gillessen, Silke
|
|
|
21 |
1 |
p. 17-19
|
artikel
|
| 51 |
Time for a shift in molecular down staging in luminal breast cancer
|
Cristofanilli, Massimo
|
|
|
21 |
1 |
p. 2-3
|
artikel
|
| 52 |
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
|
Rini, Brian I
|
|
|
21 |
1 |
p. 95-104
|
artikel
|
| 53 |
Tumour Treating Fields for mesothelioma
|
de Gooijer, Cornedine Jannette
|
|
|
21 |
1 |
p. e9
|
artikel
|
| 54 |
Tumour Treating Fields for mesothelioma
|
Barbarino, Marcella
|
|
|
21 |
1 |
p. e8
|
artikel
|
| 55 |
Tumour Treating Fields for mesothelioma – Authors' reply
|
Ceresoli, Giovanni L
|
|
|
21 |
1 |
p. e10
|
artikel
|
Tijdschrift beschrijving